Needle Free Injections Market

Needle-Free Injections Market By Product Type (Fillable and Prefilled), Technology (Jet-Based, Spring-Based, and Others), Usability (Reusable and Disposable), Application (Vaccine, Insulin, Dermatology, and Others), End-User (Hospitals, Clinics, Homecare Settings, and Others), and Geography is expected to grow at a steady CAGR forecast till 2028 owing to the increased risk of communicable infections as a result of needle injuries and needle phobia among the population.

The global needle-free injection systems market was valued at USD 12.49 billion in 2022, growing at a CAGR of 14.16% during the forecast period from 2023 to 2028 to reach USD 27.65 billion by 2028. The demand for needle-free injection systems is witnessing growth due to the rising prevalence of chronic diseases, expanding number of needle-stick injuries, increasing requirement of self-injection devices, growing number of vaccination programs, and technological innovation in product development, among other factors.

Needle-Free Injections Market Dynamics:

Needle-free injection technology encompasses a wide spectrum of drug delivery systems that help in the administration of drugs through the skin using pressure combining different modes, pushing the drug through the skin, thereby eliminating the need for a hypodermic needle.

One of the major factors influencing the growth of the needle-free injection market is the rising number of needle stick injuries among patients and caregivers. As per the data provided by the World Health Organization (2019), globally more than two million occupational exposures to sharp injuries occur among 35 million healthcare workers annually.

According to the Centers for Disease Control and Prevention (CDC) and European Agency for Safety and Health at Work (EU-Occupation Safety and Health Administration) reports published in 2019, there are more than 385,000 and 1,000,000 needle stick injury cases annually among hospital healthcare workers in the United States and Europe, respectively.

Needle-stick injuries increase the risk of more than 20 types of blood-borne infectious diseases which include HIV, hepatitis C, and hepatitis B. In addition to becoming infected with blood-borne pathogens, needle stick injuries may result in chronic diseases and also cause psychological effects. Furthermore, the management of needle sticks and sharp injuries can be cost-intensive. Therefore, owing to the abovementioned factors, there is a growing need for needle-free injection systems in the market which allow for the safe administration of drugs and therapeutics as well improve the safety prospects of healthcare providers, caregivers, and patients.

Moreover, the rising prevalence of chronic diseases, such as diabetes is also one of the major factors aiding in the needle-free injections market growth.

As per statistics by the IDF Diabetes Atlas (2022), 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. People suffering from diabetes require regular administration of insulin as one of their key treatment regimens. Many diabetes patients require multiple daily doses of insulin and often experience anxiety and pain associated with injections. Needle-free injections offer a virtually painless method for the administration of insulin by themselves in a precise manner and thereby improving the adherence to treatment and compliance by patients.

Moreover, the increased focus on providing COVID-19 vaccines to the majority of the population has also resulted in the increased demand for needle-free injection devices as many pharmaceutical companies are entering into partnerships with needle-free injection manufacturers for expanding their customer reach.

Therefore, the rising prevalence of chronic diseases, and the increasing number of needle stick injuries, coupled with the growing demand for safer self-injection devices are projected to drive the needle-free injections market growth.

However, higher requirements for training and device maintenance, limitations in the route of administration, and limitations in the variation in the design size may prove to be certain restraints to the needle-free injection market growth.

Needle-Free Injections Market Segment Analysis:

Needle-Free Injections market by Product Type (Fillable and Prefilled), Technology (Jet-Based, Spring-Based, and Others), Usability (Reusable and Disposable), Application (Vaccine, Insulin, Dermatology, and Others), End-User (Hospitals, Clinics, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the application segment of the needle-free injections market, insulin delivery needle-free injections are expected to account for a significant share of the market during the forecast period. This can be attributed to the rising prevalence of diabetic population across the globe.

Diabetic patients require multiple doses of insulin in a day, which can be a daunting process for patients in case of using conventional syringes and needles for insulin administration. These devices aid in the easy administration of insulin through the nozzle orifice, which results in the generation of a fine stream of insulin. This stream then easily penetrates the skin.

Needle-free insulin injection systems offer the least resistant path for insulin administration, thereby facilitating the even spreading of the insulin in the subcutaneous layer.

Therefore, Needle-free injection devices for insulin administration are gaining popularity and are more extensively used than for other applications owing to the above-stated reason.

North America is expected to dominate the Overall Needle-Free Injections Market:

Among all the regions, North America is expected to account for the largest share of the needle-free injection market. The growing number of chronic diseases, more focus on vaccination programs, and access to better healthcare infrastructure along with the presence of major market players in the region are predicted to be the major influencing factors in driving the overall growth of the needle-free injections market over the forecast period.

As per the data published by National Center for Immunization and Respiratory Diseases (NCIRD) under the Centers for Disease Control and Prevention 2022, influenza was associated with 9 million illnesses, 4 million medical visits, and about 10,000 hospitalizations in the United States between 2021 and 2022.

Needle-free injection systems are used in the administration of different vaccines including influenza vaccines. CDC works each year to increase the number of people who receive a flu vaccine and eliminate barriers to vaccination. As flu vaccines are commonly administered in pediatric patients, these systems help in the easy administration of vaccines to children and people suffering from needle phobia, and other apprehensions. One example of this is the PharmaJet Stratis Needle-Free Injector which is the first needleless intramuscular Jet Injector approved by the US Food and Drug Administration for the delivery of an influenza vaccine.

Moreover, the well-established healthcare infrastructure in the country which can be supported by the high per capita healthcare expenditure in the country as well as the presence of a highly aware patient population further encourages people to opt for such devices.

Therefore, the above-mentioned factors are expected to propel the growth of the North America Needle-free injections market.

Needle-Free Injections Market Key Players:

Some of the key market players operating in the needle-free injection systems market include IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc, Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC., Portal Instruments, D'Antonio Consultants International, Inc and others.

Recent Developmental Activities in Needle-Free Injections Market:

• In August 2022, PharmaJet and their partner Zydus Cadila announced the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine- ZyCoV-D is exclusively administered by the deployment of the PharmaJet Tropis® Needle-free Injection System.

Key Takeaways from the Needle-Free Injections Market Report Study

• Market size analysis for current needle-free injections market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global needle-free injections market
• Various opportunities available for the other competitor in the needle-free injections market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current needle-free injections market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for needle-free injection market growth in the coming future?

Target Audience who can be benefited from this Needle-Free Injections Market Report Study

• Needle-free injection systems products providers
• Research organizations and consulting companies
• Needle-free injection systems -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in needle-free injections market
• Various End-Users who want to know more about the needle-free injections market and the latest technological developments in the needle-free injections market

Frequently Asked Questions for Needle-Free Injections Market:

1. What is a Needle Free Injection System?

Needle-free injection technology encompasses a wide spectrum of technology that includes a wide variety of drug delivery systems that help in the administration of drugs through the skin using pressure combining different modes, pushing the drug through the skin, thereby eliminating the need for a hypodermic needle.

2. What is the market for global needle-free injections?

The global needle-free injection systems market was valued at USD 12.49 billion in 2022, growing at a CAGR of 14.16% during the forecast period from 2023 to 2028 to reach USD 27.65 billion by 2028.

3. What are the drivers for the global needle-free injections market?

The major drivers of the global needle-free injections market growth are the rising prevalence of chronic diseases, an increasing number of needle stack and sharp injuries, and a rising number of trauma cases, among other factors.

4. Who are the key players operating in the global needle-free injections market?

Some of the key market players operating in the needle-free injection systems market include IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc, Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC., Portal Instruments, D'Antonio Consultants International, Inc and others.

5. Which region has the highest share in the needle-free injections market?

North America is expected to dominate the overall needle-free injections market during the forecast period, 2023 to 2028. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of chronic diseases, increased focus on vaccination programs, improving the safety of healthcare providers, and increasing collaborations between key market players in the region.